Pramel13os, an enigmatic non-coding RNA located on the opposite strand of PRAME-like 13, presents a complex puzzle in our understanding of its biological function. Despite extensive research, its specific role remains elusive, adding to the intricacies of non-coding RNA biology. While the protein-coding PRAME-like 13 on the opposite strand suggests potential cis-regulation, Pramel13os's precise molecular functions and interactions are not well-defined. Its sequence characteristics, devoid of a protein-coding potential, hint at possible roles in transcriptional regulation, chromatin organization, or participation in intricate cellular networks. The lack of a known function underscores the challenges in deciphering the roles of non-coding RNAs, emphasizing the need for further exploration to unravel the intricacies of Pramel13os in cellular processes.
In terms of inhibition, a diverse set of chemicals targeting various cellular pathways reveals the complexity of regulating Pramel13os expression. These inhibitors act through distinct mechanisms, such as epigenetic modifications, interference with specific signaling cascades, and induction of DNA damage, reflecting the multifaceted regulatory landscape surrounding Pramel13os. The involvement of histone deacetylase inhibitors, DNA methyltransferase inhibitors, and bromodomain-containing protein inhibitors highlights the potential impact of epigenetic modifications on Pramel13os transcription. Additionally, inhibitors targeting signaling pathways, including TGF-β/Smad, PI3K/AKT, and MAPK/ERK, suggest a role for Pramel13os in these cellular cascades. The complexity of its regulatory network, as indicated by a wide array of inhibitors, implies a versatile and dynamic involvement in cellular homeostasis, which demands further investigation to unveil the intricate mechanisms governing Pramel13os function and regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A inhibits Pramel13os through histone deacetylase (HDAC) inhibition. By preventing histone deacetylation, it maintains a condensed chromatin structure, limiting transcription of Pramel13os. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine inhibits Pramel13os via DNA methyltransferase inhibition. Hypermethylation induced by 5-Azacytidine leads to chromatin condensation and reduced transcriptional activity of Pramel13os. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 inhibits Pramel13os by targeting bromodomain-containing proteins (BRD). Inhibition of BRD interferes with transcription initiation, reducing the expression of Pramel13os. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 inhibits Pramel13os through TGF-β/Smad signaling pathway blockade. By targeting the TGF-β receptor, it prevents downstream signaling, influencing the transcriptional activity of Pramel13os. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits Pramel13os by blocking the PI3K/AKT pathway. As a PI3K inhibitor, LY294002 disrupts downstream signaling, diminishing Pramel13os expression. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib inhibits Pramel13os through the MAPK/ERK pathway blockade. As a MEK inhibitor, AZD6244 disrupts the MAPK signaling cascade, leading to decreased Pramel13os expression. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin inhibits Pramel13os by inducing DNA damage and apoptosis, leading to reduced transcription and expression of Pramel13os. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine inhibits Pramel13os via DNA methyltransferase inhibition. Inducing hypomethylation, it alters chromatin structure, affecting the transcriptional activity of Pramel13os. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits Pramel13os by blocking the PI3K/AKT pathway. As a PI3K inhibitor, Wortmannin disrupts downstream signaling, diminishing Pramel13os expression. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits Pramel13os through NF-κB pathway blockade. By suppressing NF-κB activation, it influences the transcriptional regulation of Pramel13os. | ||||||